Developer docs
API playgroundTry for free, no card

Search company profiles

S-Alpha Therapeutics

Full company profile

uuid0002btg

Namestring
S-Alpha Therapeutics
Legal namestring
주식회사 에스알파테라퓨틱스 (S-Alpha Therapeutics, Inc.)
Websiteurl
salphadtx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

S-Alpha Therapeutics is a Seoul-based digital therapeutics company founded in 2019 that develops evidence-based software medical devices (SaMD) for unmet medical needs, using data-based software technology that combines bio and digital approaches. The company's lead asset is SAT-001 (MyoHabit), a software-based digital therapeutic designed to delay myopia progression in children aged 5–9; a 48-week confirmatory trial with 111 patients demonstrated a statistically significant reduction in axial length increase with no device-related adverse reactions. S-Alpha operates a broader pipeline of six software product technologies spanning pediatric myopia (SAT-001), mild cognitive impairment (SAT-002), cancer cachexia (SAT-003), pediatric organ function (SAT-006), immunology/infectious disease (SAT-008), and stress disorders (SAT-014).

Short descriptiontext

S-Alpha Therapeutics is a Seoul-based digital therapeutics company developing evidence-based software medical devices, with lead product SAT-001 (MyoHabit) for pediatric myopia progression and a pipeline across cognitive, oncology, and stress-related indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeocho, South Korea
HQ citystring
Seocho
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, software medical devices, pediatric myopia treatment, digital healthcare software, evidence-based therapeutics
Industry3 codes
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAN
DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Digital Therapeutic Device Sales
TypeOne Time License
Description

Revenue expected from SAT-001 (MyoHabit) digital therapeutic device upon regulatory approval in Korea and other markets, through partnership-driven commercialization model

startupn.kr
2Pipeline Product Licensing
TypeLicensing Royalties
Description

Additional revenue streams from other pipeline products (SAT-002, SAT-003, SAT-006, SAT-008, SAT-014) through clinical validation and subsequent commercialization

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1SAT-001 (MyoHabit)
Description

Digital therapeutic device for pediatric myopia progression inhibition.

salphadtx.com
+5 more records
Core offering1 text field

S-Alpha Therapeutics develops and commercializes software-based digital therapeutics (SaMD) that deliver evidence-based, non-invasive treatments for unmet medical needs. The lead product SAT-001 (MyoHabit) is a digital therapeutic device for pediatric myopia progression inhibition, supported by confirmatory clinical trial data. The company maintains a broader pipeline covering mild cognitive impairment, cancer cachexia, pediatric organ function, immunology/infectious disease, and stress disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Statistically significant delay in axial length increase in pediatric myopia patients aged 5-9 over 48 weeks
Product overview1 text field

S-Alpha Therapeutics is a digital therapeutics (DTx) company developing data-based software technologies that provide evidence-based treatment methods for unmet medical needs. The company operates a multi-product pipeline of software-based medical devices (SaMD). The core product is SAT-001 (MyoHabit), a digital therapeutic for pediatric myopia progression, which has completed confirmatory clinical trials and is planned for regulatory filing. Additional pipeline products include SAT-002 (mild cognitive impairment), SAT-003 (cancer cachexia), SAT-006 (pediatric organ function), SAT-008 (immunology/infectious disease), and SAT-014 (stress disorders).

Product and service6 records
1SAT-001 (MyoHabit)
CategoryDigital Therapeutics - Pediatric Myopia
Description

Software-based digital therapeutic device designed to delay myopia progression in children aged 5-9 years; evidence-based, non-invasive treatment for pediatric ophthalmology that demonstrated statistically significant delay in axial length increase over 48 weeks with no device-related adverse reactions in a 111-patient confirmatory trial.

2SAT-002
CategoryDigital Therapeutics - Mild Cognitive Impairment
Description

Software product technology designed to inhibit mild cognitive impairment progression, addressing unmet medical needs in cognitive health as part of S-Alpha's multi-indication digital therapeutics pipeline.

3SAT-003
CategoryDigital Therapeutics - Cancer Cachexia
Description

Software product technology aimed at improving cancer cachexia (cancer-related wasting syndrome), part of S-Alpha's digital therapeutics pipeline targeting oncology-related conditions.

4SAT-006
CategoryDigital Therapeutics - Pediatric Organ Function
Description

Software product technology designed to improve long-term organ function in pediatric patients, extending S-Alpha's pediatric digital therapeutics focus beyond myopia into broader pediatric care.

5SAT-008
CategoryDigital Therapeutics - Immunology/Infectious Disease
Description

Software product technology related to immunology and infectious diseases, part of S-Alpha's multi-indication digital therapeutics pipeline.

6SAT-014
CategoryDigital Therapeutics - Stress Disorders
Description

Software product technology designed to improve stress disorder conditions, part of S-Alpha's multi-indication digital therapeutics pipeline targeting mental health and stress-related conditions.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Rohto Pharmaceutical
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-27
Description

Technology transfer and partnership agreement with Japan's Rohto Pharmaceutical for global commercialization of digital therapeutic products including SAT-001 (MyoHabit)

startupn.kr
2JungKookDang
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-27
Description

Technology transfer and partnership agreement for global commercialization of digital therapeutic products

startupn.kr
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Outsourced clinical trial related business operations and related data confirmation and storage

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eyerising develops Diffusion Optics Technology for slowing pediatric myopia progression, making it the closest direct competitor to S-Alpha's SAT-001 (MyoHabit) on indication, patient population (children), and mechanism category (non-pharmaceutical, device-based myopia management).

TypeDirect peer
Description

Dopavision is developing a digital therapeutic (MyopiaX) that uses controlled light stimuli delivered via a smartphone app to slow pediatric myopia progression — directly overlapping with S-Alpha's lead indication and DTx delivery model.

TypeDirect peer
Description

Akili pioneered FDA-cleared prescription digital therapeutics (EndeavorRx for pediatric ADHD) and is a direct peer in pediatric, prescription-grade DTx — same regulatory pathway and prescriber channel as S-Alpha's SAT-001.

TypeDirect peer
Description

Click Therapeutics develops prescription digital therapeutics across multiple indications with pharma-style clinical development, sharing S-Alpha's pipeline breadth, regulatory strategy, and partnership-driven commercialization model.

TypeDirect peer
Description

Big Health creates evidence-based digital therapeutics (e.g., Sleepio for insomnia) targeting unmet needs via clinical validation — directly comparable to S-Alpha's evidence-first DTx approach and SaaMD development model.

TypeDirect peer
Description

Kaia Health develops digital therapeutics for musculoskeletal and chronic conditions using AI and behavioral science, overlapping with S-Alpha's multi-indication, evidence-based DTx pipeline and self-management software model.

TypeDirect peer
Description

Voluntis (now part of Aptar Digital Health) develops prescription digital therapeutics for chronic conditions, providing direct comparability with S-Alpha on SaMD regulatory pathway, partner-led commercialization, and multi-indication pipeline strategy.

TypeEmerging player
Description

Cognoa develops AI-driven pediatric diagnostic and therapeutic digital health solutions (e.g., Canvas Dx for autism), aligning with S-Alpha on the pediatric focus and AI/software-as-medical-device regulatory approach.

TypeBroad incumbent
Description

Otsuka received FDA clearance for Rejoyn, a prescription digital therapeutic for depression, establishing a large-pharma precedent for DTx commercialization that mirrors S-Alpha's pharma-partnered (Rohto) go-to-market.

10Rohto Pharmaceutical
TypeOthers
Description

Rohto is both a strategic investor ($16.7M round in 2024) and commercialization partner for S-Alpha in Japan; as an established Japanese OTC and ophthalmology player, it is a key ecosystem partner comparable in distribution and category overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

S-Alpha Therapeutics

Digital Therapeuticssalphadtx.com

S-Alpha Therapeutics is a Seoul-based digital therapeutics company developing evidence-based software medical devices, with lead product SAT-001 (MyoHabit) for pediatric myopia progression and a pipeline across cognitive, oncology, and stress-related indications.

What S-Alpha Therapeutics does

S-Alpha Therapeutics is a Seoul-based digital therapeutics company founded in 2019 that develops evidence-based software medical devices (SaMD) for unmet medical needs, using data-based software technology that combines bio and digital approaches. The company's lead asset is SAT-001 (MyoHabit), a software-based digital therapeutic designed to delay myopia progression in children aged 5–9; a 48-week confirmatory trial with 111 patients demonstrated a statistically significant reduction in axial length increase with no device-related adverse reactions. S-Alpha operates a broader pipeline of six software product technologies spanning pediatric myopia (SAT-001), mild cognitive impairment (SAT-002), cancer cachexia (SAT-003), pediatric organ function (SAT-006), immunology/infectious disease (SAT-008), and stress disorders (SAT-014).

S-Alpha Therapeutics firmographics

Firmographics
Name
S-Alpha Therapeutics
Legal name
주식회사 에스알파테라퓨틱스 (S-Alpha Therapeutics, Inc.)
Website
https://salphadtx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
S-Alpha Therapeutics is a Seoul-based digital therapeutics company developing evidence-based software medical devices, with lead product SAT-001 (MyoHabit) for pediatric myopia progression and a pipeline across cognitive, oncology, and stress-related indications.
Ownership category
akta.pro rank

S-Alpha Therapeutics industry classification

Industry
Product category
Digital Therapeutics
NAICS
Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAN
DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital therapeutics
  • Software medical devices
  • Pediatric myopia treatment
  • Digital healthcare software
  • Evidence-based therapeutics

Where S-Alpha Therapeutics is headquartered

Location

Headquarters

HQ city
Seocho
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

S-Alpha Therapeutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Digital Therapeutic Device Sales: Revenue expected from SAT-001 (MyoHabit) digital therapeutic device upon regulatory approval in Korea and other markets, through partnership-driven commercialization model
  2. Pipeline Product Licensing: Additional revenue streams from other pipeline products (SAT-002, SAT-003, SAT-006, SAT-008, SAT-014) through clinical validation and subsequent commercialization

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

S-Alpha Therapeutics product offering

Product offering

Core offering

S-Alpha Therapeutics develops and commercializes software-based digital therapeutics (SaMD) that deliver evidence-based, non-invasive treatments for unmet medical needs. The lead product SAT-001 (MyoHabit) is a digital therapeutic device for pediatric myopia progression inhibition, supported by confirmatory clinical trial data. The company maintains a broader pipeline covering mild cognitive impairment, cancer cachexia, pediatric organ function, immunology/infectious disease, and stress disorders.

Product overview

S-Alpha Therapeutics is a digital therapeutics (DTx) company developing data-based software technologies that provide evidence-based treatment methods for unmet medical needs. The company operates a multi-product pipeline of software-based medical devices (SaMD). The core product is SAT-001 (MyoHabit), a digital therapeutic for pediatric myopia progression, which has completed confirmatory clinical trials and is planned for regulatory filing. Additional pipeline products include SAT-002 (mild cognitive impairment), SAT-003 (cancer cachexia), SAT-006 (pediatric organ function), SAT-008 (immunology/infectious disease), and SAT-014 (stress disorders).

Differentiator

Problem solved

Functional benefit

Brands

  • SAT-001 (MyoHabit): Digital therapeutic device for pediatric myopia progression inhibition.
  • SAT-002
  • SAT-003
  • SAT-006
  • SAT-008
  • SAT-014

Products and services

  • SAT-001 (MyoHabit) Software-based digital therapeutic device designed to delay myopia progression in children aged 5-9 years; evidence-based, non-invasive treatment for pediatric ophthalmology that demonstrated statistically significant delay in axial length increase over 48 weeks with no device-related adverse reactions in a 111-patient confirmatory trial.
  • SAT-002 Software product technology designed to inhibit mild cognitive impairment progression, addressing unmet medical needs in cognitive health as part of S-Alpha's multi-indication digital therapeutics pipeline.
  • SAT-003 Software product technology aimed at improving cancer cachexia (cancer-related wasting syndrome), part of S-Alpha's digital therapeutics pipeline targeting oncology-related conditions.
  • SAT-006 Software product technology designed to improve long-term organ function in pediatric patients, extending S-Alpha's pediatric digital therapeutics focus beyond myopia into broader pediatric care.
  • SAT-008 Software product technology related to immunology and infectious diseases, part of S-Alpha's multi-indication digital therapeutics pipeline.
  • SAT-014 Software product technology designed to improve stress disorder conditions, part of S-Alpha's multi-indication digital therapeutics pipeline targeting mental health and stress-related conditions.

Quantifiable outcome

  • Statistically significant delay in axial length increase in pediatric myopia patients aged 5-9 over 48 weeks

Companies that use S-Alpha Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

S-Alpha Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

S-Alpha Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Rohto PharmaceuticalcoreOEM/ Whitelabel/ Licensing Partner · 27 March 2026Technology transfer and partnership agreement with Japan's Rohto Pharmaceutical for global commercialization of digital therapeutic products including SAT-001 (MyoHabit)
  • JungKookDangcoreOEM/ Whitelabel/ Licensing Partner · 27 March 2026Technology transfer and partnership agreement for global commercialization of digital therapeutic products
  • LSK Global Pharma ServicesminorImplementation/ SI/ Consulting PartnerOutsourced clinical trial related business operations and related data confirmation and storage

Scale indicators4 records

Expansion highlights5 records

S-Alpha Therapeutics competitors and assessment

Company assessment

Direct peers

  • Eyerising International (formerly SightGlass Vision): Eyerising develops Diffusion Optics Technology for slowing pediatric myopia progression, making it the closest direct competitor to S-Alpha's SAT-001 (MyoHabit) on indication, patient population (children), and mechanism category (non-pharmaceutical, device-based myopia management).
  • Dopavision: Dopavision is developing a digital therapeutic (MyopiaX) that uses controlled light stimuli delivered via a smartphone app to slow pediatric myopia progression — directly overlapping with S-Alpha's lead indication and DTx delivery model.
  • Akili Interactive: Akili pioneered FDA-cleared prescription digital therapeutics (EndeavorRx for pediatric ADHD) and is a direct peer in pediatric, prescription-grade DTx — same regulatory pathway and prescriber channel as S-Alpha's SAT-001.
  • Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across multiple indications with pharma-style clinical development, sharing S-Alpha's pipeline breadth, regulatory strategy, and partnership-driven commercialization model.
  • Big Health: Big Health creates evidence-based digital therapeutics (e.g., Sleepio for insomnia) targeting unmet needs via clinical validation — directly comparable to S-Alpha's evidence-first DTx approach and SaaMD development model.
  • Kaia Health: Kaia Health develops digital therapeutics for musculoskeletal and chronic conditions using AI and behavioral science, overlapping with S-Alpha's multi-indication, evidence-based DTx pipeline and self-management software model.
  • Voluntis (Aptar Digital Health): Voluntis (now part of Aptar Digital Health) develops prescription digital therapeutics for chronic conditions, providing direct comparability with S-Alpha on SaMD regulatory pathway, partner-led commercialization, and multi-indication pipeline strategy.

Emerging players

  • Cognoa: Cognoa develops AI-driven pediatric diagnostic and therapeutic digital health solutions (e.g., Canvas Dx for autism), aligning with S-Alpha on the pediatric focus and AI/software-as-medical-device regulatory approach.

Broad incumbents

  • Otsuka Pharmaceutical: Otsuka received FDA clearance for Rejoyn, a prescription digital therapeutic for depression, establishing a large-pharma precedent for DTx commercialization that mirrors S-Alpha's pharma-partnered (Rohto) go-to-market.

Others

  • Rohto Pharmaceutical: Rohto is both a strategic investor ($16.7M round in 2024) and commercialization partner for S-Alpha in Japan; as an established Japanese OTC and ophthalmology player, it is a key ecosystem partner comparable in distribution and category overlap.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key highlights6 records

Customer concentration

S-Alpha Therapeutics social profiles

Digital presence

S-Alpha Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

S-Alpha Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

S-Alpha Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

S-Alpha Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about S-Alpha Therapeutics

What does S-Alpha Therapeutics do?

S-Alpha Therapeutics develops and commercializes software-based digital therapeutics (SaMD) that deliver evidence-based, non-invasive treatments for unmet medical needs. The lead product SAT-001 (MyoHabit) is a digital therapeutic device for pediatric myopia progression inhibition, supported by confirmatory clinical trial data. The company maintains a broader pipeline covering mild cognitive impairment, cancer cachexia, pediatric organ function, immunology/infectious disease, and stress disorders.

Is S-Alpha Therapeutics a public or private company?

S-Alpha Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was S-Alpha Therapeutics founded?

S-Alpha Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is S-Alpha Therapeutics based?

S-Alpha Therapeutics is headquartered in Seocho, South Korea, in the Asia region.

How does S-Alpha Therapeutics make money?

Two revenue lines are on record. Digital Therapeutic Device Sales are the primary driver. The others are pipeline Product Licensing.

Who are S-Alpha Therapeutics's main competitors?

Direct peers on record are Eyerising International (formerly SightGlass Vision), Dopavision, Akili Interactive, Click Therapeutics, Big Health, Kaia Health and Voluntis (Aptar Digital Health). Cognoa is listed as an emerging player. Otsuka Pharmaceutical is listed as a broad incumbent. Rohto Pharmaceutical is listed as an others.

Does S-Alpha Therapeutics have an API?

No public API is recorded for S-Alpha Therapeutics.

What industry is S-Alpha Therapeutics in?

S-Alpha Therapeutics's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAN, DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA). Its NAICS code is 5417 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
스타트업엔(StartupN)Is a new path opening for the treatment of pediatric myopia? SR Alpha Terra reveals clinical results of DTx 'SAT-001'.SR Alpha Therapeutics presented clinical results of its digital therapeutic device SAT-001 (MyoHabit) for pediatric myopia at the Korean Ophthalmological Society's conference in Busan on March 27. The confirmatory clinical trial over 48 weeks with 111 patients aged 5-9 demonstrated statistically significant delay in axial length increase with no device-related adverse reactions. The company plans to file for product approval with Korea's Ministry of Food and Drug Safety in April and has secured technology transfer and partnership agreements with Japan's Rohto Pharmaceutical and JungKookDang for global commercialization.KoreaTechDeskS-Alpha Therapeutics secures Series B funding for myopia-digital treatment - KoreaTechDeskS-Alpha Therapeutics has secured 11 billion won ($8.4 million) in Series B funding led by Korea Investment Partners and other investors to advance its digital myopia treatment, SAT-001. The company plans to use the capital to accelerate domestic and international clinical trials for the device, which aims to inhibit myopia progression in children through non-contact gaming interventions. This funding supports S-Alpha's broader goal of developing innovative digital treatments for global health issues.BioSpaceS-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A FundingS-Alpha Therapeutics raised $8.7 million in Series A funding led by STIC Ventures, with participation from existing and new investors including Korea Investment Partners and Stonebridge Ventures. The company plans to use the capital to conduct clinical trials for its pediatric myopia product SAT-001 in South Korea and the US, as well as to validate other pipeline candidates like SAT-008.FinSMEsS-Alpha Therapeutics Raises $2.7M in Seed FundingS-Alpha Therapeutics, a Seoul-based digital therapeutics startup, closed a $2.7M seed round led by Hana Ventures and others. The funds will support US clinical trials for its eye-disease treatment SAT-001, which is in regulatory submission in Korea and has met with the USFDA.BioSpaceDigital Therapeutics Startup S-Alpha Therapeutics Raises $2.7M in Seed FundingS-Alpha Therapeutics, a Seoul-based digital therapeutics startup, completed a $2.7 million USD seed funding round on November 20th, led by Hana Ventures with participation from STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. The company previously received an initial strategic investment from LegoChem Biosciences in February 2020. S-Alpha intends to use the funds to execute clinical trials in the United States for its development-stage digital therapeutic application SAT-001, intended to treat eye disease.